In order to access this content you must be logged in and have a subscription to PL Intelligence.

PL Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Vion and Yale present preclinical data on Sulfonyl Hydrazine
ALZA has anti-cancer agent approved for the treatment of ovarian cancer
MGI PHARMA announces exclusive license agreement
Banyu and Pharmacia to develop anti-cancer agent
Viragen licenses 'Anti-CD55 antibody' cancer therapy from Cancer Research Technology
Antisense research identifies anti-cancer agent
MGI PHARMA to Acquire Zycos; Pivotal Phase 3 Program for ZYC101a Planned for Early 2005